Insulet’s (PODD) “Hold” Rating Reiterated at Truist Financial

Insulet (NASDAQ:PODD)‘s stock had its “hold” rating reiterated by analysts at Truist Financial in a research report issued on Monday, Benzinga reports. They presently have a $160.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $153.00. Truist Financial‘s price objective points to a potential upside of 9.21% from the stock’s current price.

A number of other research firms have also recently commented on PODD. Citigroup lifted their target price on shares of Insulet from $150.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday. BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Stifel Nicolaus cut their price target on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Sanford C. Bernstein raised their price target on shares of Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a research note on Monday, September 21st. Twelve equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $185.67.

Insulet Stock Performance

Insulet stock opened at $146.51 on Monday. The stock has a 50-day moving average of $141.97 and a two-hundred day moving average of $176.65. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet has a one year low of $126.40 and a one year high of $354.88. The stock has a market cap of $10.16 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.12 and a beta of 1.06.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. During the same quarter in the previous year, the firm earned $1.24 earnings per share. The company’s revenue was up 19.2% on a year-over-year basis. On average, research analysts anticipate that Insulet will post 6.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Elevation Wealth Partners LLC lifted its holdings in shares of Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 104 shares during the period. Activest Wealth Management boosted its position in Insulet by 186.3% in the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 149 shares during the last quarter. WPG Advisers LLC increased its holdings in Insulet by 169.3% in the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 171 shares during the period. State of Wyoming increased its holdings in Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after buying an additional 73 shares during the period. Finally, Continuum Advisory LLC acquired a new position in Insulet in the 2nd quarter worth approximately $46,000.

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.

Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Insulet serves customers in the United States and international markets.